Australia markets close in 3 hours 7 minutes

Zealand Pharma A/S (0NZU.IL)

IOB - IOB Delayed price. Currency in DKK
Add to watchlist
671.25+22.75 (+3.51%)
At close: 06:52PM GMT
Full screen
Previous close648.50
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's range0.00 - 0.00
52-week range
Volume2,908
Avg. volume103,194
Market cap40.023B
Beta (5Y monthly)0.62
PE ratio (TTM)N/A
EPS (TTM)-15.13
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Zealand Pharma Announces Financial Results for the Full Year 2023

    Company announcement - No. 9 / 2024 Zealand Pharma Announces Financial Results for the Full Year 2023 Significant progress delivered across our obesity and rare disease assets while building a solid financial position Positive results achieved for petrelintide in 6-week Phase 1 trial and clinical advancement of dapiglutide and petrelintide towards obesity data readouts in 2024Positive results announced in Boehringer Ingelheim Phase 2 clinical trials for survodutide in obesity and global Phase 3

  • Yahoo Finance Video

    Zealand Pharma, Gap, Freshpet: Trending Tickers

    Zealand Pharma (ZEAL.CO) stock skyrockets on positive results from a liver disease treatment trial. JPMorgan analysts upgrade retailer The Gap (GPS) to Neutral, raising the price target to $20. Pet food company Freshpet (FRPT) sees its stock jump after beating fourth-quarter earnings estimates and issuing strong sales guidance. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Luke Carberry Mogan.

  • GlobeNewswire

    Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis

    Company announcement - No. 8 / 2024 Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH)*, after meeting its primary and key secondary endpoint following 48 weeks of treatment versus placebo in a Phase 2 trialSurvodutide, a novel